{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:19:48Z","timestamp":1793812788122,"version":"4.6.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Biol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cervical cancer remains a leading cause of cancer-related mortality in women, with high-risk HPV types (16, 18, 31, 33, 45, 52, and 58) playing a key role in its development. Platinum-based chemotherapy is standard for recurrent or metastatic cervical cancer, but platinum resistance remains a major challenge. The link between HPV infection and platinum resistance is not well understood. Tumor organoids offer a physiologically relevant model for investigating drug resistance mechanisms in cervical cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We successfully established 37 cervical cancer organoids (CCOs), with 27 expanded for characterization and drug sensitivity testing. CCOs recapitulated the biomarker expression patterns and genomic features of their corresponding tissues. Drug sensitivity assays revealed increased cisplatin\/carboplatin resistance in the non-HPV16 high-risk HPV CCOs subgroup, compared to HPV-negative CCOs. Single-cell RNA sequencing identified diverse cellular populations within CCOs, with platinum-resistant CCOs showing enhanced DNA repair, activation of the PI3K\/AKT pathway, and suppressed apoptotic signaling. We also found that the PI3K\/AKT inhibitor BYL719 enhanced the response to cisplatin and carboplatin in non-HPV16 high-risk HPV CCOs but not in HPV-negative CCOs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Cervical cancer organoids faithfully replicate the histopathological and genomic characteristics of their parental tumors, demonstrating their potential as preclinical models for studying cancer progression and drug resistance. Our findings suggest that the non-HPV16 high-risk HPV infections may contribute to increased platinum resistance through enhanced DNA repair mechanisms, increased PI3K\/AKT activation and suppressed apoptosis, providing new insights for personalized cervical cancer treatment. The PI3K\/AKT inhibitor BYL719 may serve as a potential therapeutic adjunct to enhance platinum efficacy in those patients with platinum-resistant cervical cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12915-026-02665-w","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:55:32Z","timestamp":1782449732000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Decoding the association between platinum resistance and HPV status in cervical cancer using organoid models"],"prefix":"10.1186","volume":"24","author":[{"given":"Bin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongkai","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongyang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingliang","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huayang","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"2665_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1105468","volume":"13","author":"L Ji","year":"2023","unstructured":"Ji L, Chen M, Yao L. Strategies to eliminate cervical cancer in China. Front Oncol. 2023;13:1105468.","journal-title":"Front Oncol"},{"issue":"sup244","key":"2665_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3109\/00365513.2014.936683","volume":"74","author":"KU Petry","year":"2014","unstructured":"Petry KU. HPV and cervical cancer. Scand J Clin Lab Invest. 2014;74(sup244):59\u201362.","journal-title":"Scand J Clin Lab Invest"},{"key":"2665_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvr.2021.200221","volume":"12","author":"S Lagstr\u00f6m","year":"2021","unstructured":"Lagstr\u00f6m S, L\u00f8vestad AH, Umu SU, Ambur OH, Nyg\u00e5rd M, Rounge TB, et al. HPV16 and HPV18 type-specific APOBEC3 and integration profiles in different diagnostic categories of cervical samples. Tumour Virus Res. 2021;12:200221.","journal-title":"Tumour Virus Res"},{"issue":"null","key":"2665_CR4","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.2147\/DDDT.S106412","volume":"10","author":"H Zhu","year":"2016","unstructured":"Zhu H, Luo H, Zhang W, Shen Z, Hu X, Zhu X. Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Des Devel Ther. 2016;10(null):1885\u201395.","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"2665_CR5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ygyno.2014.01.042","volume":"133","author":"D Lorusso","year":"2014","unstructured":"Lorusso D, Petrelli F, Coinu A, Raspagliesi F, Barni S. A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. Gynecol Oncol. 2014;133(1):117\u201323.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"2665_CR6","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1016\/j.ygyno.2007.07.043","volume":"107","author":"JS Saldivar","year":"2007","unstructured":"Saldivar JS, Wu X, Follen M, Gershenson D. Nucleotide excision repair pathway review I: implications in ovarian cancer and platinum sensitivity. Gynecol Oncol. 2007;107(1):S56\u201371.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"2665_CR7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.bcp.2015.03.006","volume":"95","author":"S-J Chen","year":"2015","unstructured":"Chen S-J, Kuo C-C, Pan H-Y, Tsou T-C, Yeh S-C, Chang J-Y. Mechanistic basis of a combination D-penicillamine and platinum drugs synergistically inhibits tumor growth in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo. Biochem Pharmacol. 2015;95(1):28\u201337.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"2665_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/srep02899","volume":"3","author":"T Okada","year":"2013","unstructured":"Okada T, Murata K, Hirose R, Matsuda C, Komatsu T, Ikekita M, et al. Upregulated expression of FGF13\/FHF2 mediates resistance to platinum drugs in cervical cancer cells. Sci Rep. 2013;3(1):2899.","journal-title":"Sci Rep"},{"issue":"31","key":"2665_CR9","doi-asserted-by":"publisher","first-page":"49310","DOI":"10.18632\/oncotarget.10336","volume":"7","author":"S-J Chen","year":"2016","unstructured":"Chen S-J, Kuo C-C, Pan H-Y, Tsou T-C, Yeh S-C, Chang J-Y. Desferal regulates hCtr1 and transferrin receptor expression through Sp1 and exhibits synergistic cytotoxicity with platinum drugs in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo. Oncotarget. 2016;7(31):49310.","journal-title":"Oncotarget"},{"issue":"3","key":"2665_CR10","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.drup.2005.04.006","volume":"8","author":"V Brabec","year":"2005","unstructured":"Brabec V, Kasparkova J. Modifications of DNA by platinum complexes: relation to resistance of tumors to platinum antitumor drugs. Drug Resist Updates. 2005;8(3):131\u201346.","journal-title":"Drug Resist Updates"},{"key":"2665_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.803114","volume":"13","author":"E Mahapatra","year":"2022","unstructured":"Mahapatra E, Sengupta D, Kumar R, Dehury B, Das S, Roy M, et al. Phenethylisothiocyanate potentiates platinum therapy by reversing cisplatin resistance in cervical cancer. Front Pharmacol. 2022;13:803114.","journal-title":"Front Pharmacol"},{"issue":"5","key":"2665_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13051168","volume":"13","author":"R Masadah","year":"2021","unstructured":"Masadah R, Rauf S, Pratama MY, Tiribelli C, Pascut D. The role of microRNAs in the cisplatin-and radio-resistance of cervical cancer. Cancers. 2021;13(5):1168.","journal-title":"Cancers"},{"key":"2665_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0662-9","author":"H Xu","year":"2018","unstructured":"Xu H, Lyu X, Yi M, Zhao W, Song Y, Wu K. Organoid technology and applications in cancer research. J Hematol Oncol. 2018. https:\/\/doi.org\/10.1186\/s13045-018-0662-9.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"2665_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cells8050470","volume":"8","author":"J Kondo","year":"2019","unstructured":"Kondo J, Inoue M. Application of cancer organoid model for drug screening and personalized therapy. Cells. 2019;8(5):470.","journal-title":"Cells"},{"issue":"10","key":"2665_CR15","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1038\/s41596-020-0379-4","volume":"15","author":"E Driehuis","year":"2020","unstructured":"Driehuis E, Kretzschmar K, Clevers H. Establishment of patient-derived cancer organoids for drug-screening applications. Nat Protoc. 2020;15(10):3380\u2013409.","journal-title":"Nat Protoc"},{"key":"2665_CR16","doi-asserted-by":"crossref","unstructured":"Cochrane DR, Campbell KR, Greening K, Ho GC, Hopkins J, Bui M, Douglas JM, Sharlandjieva V, Munzur AD, Lai D et al: Single cell transcriptomes of normal endometrial derived organoids uncover novel cell type markers and cryptic differentiation of primary tumours. J Pathol. 2020, 252(2):201\u2013214 %U https:\/\/onlinelibrary.wiley.com\/doi\/210.1002\/path.5511.","DOI":"10.1002\/path.5511"},{"issue":"2","key":"2665_CR17","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.stemcr.2018.07.004","volume":"11","author":"S Haider","year":"2018","unstructured":"Haider S, Meinhardt G, Saleh L, Kunihs V, Gamperl M, Kaindl U, et al. Self-renewing trophoblast organoids recapitulate the developmental program of the early human placenta. Stem Cell Reports. 2018;11(2):537\u201351.","journal-title":"Stem Cell Reports"},{"issue":"5","key":"2665_CR18","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s41591-019-0422-6","volume":"25","author":"O Kopper","year":"2019","unstructured":"Kopper O, de Witte CJ, Lohmussaar K, Valle-Inclan JE, Hami N, Kester L, et al. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nat Med. 2019;25(5):838\u201349.","journal-title":"Nat Med"},{"key":"2665_CR19","doi-asserted-by":"crossref","unstructured":"Semertzidou A, Brosens JJ, McNeish I, Kyrgiou M: Organoid models in gynaecological oncology research. Cancer Treatment Reviews 2020, 90:102103 %U https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737220301419.","DOI":"10.1016\/j.ctrv.2020.102103"},{"issue":"1","key":"2665_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41418-020-0565-5","volume":"28","author":"L Alzamil","year":"2021","unstructured":"Alzamil L, Nikolakopoulou K, Turco MY. Organoid systems to study the human female reproductive tract and pregnancy. Cell Death Differ. 2021;28(1):35\u201351.","journal-title":"Cell Death Differ"},{"key":"2665_CR21","doi-asserted-by":"crossref","unstructured":"Maenhoudt N, Defraye C, Boretto M, Jan Z, Heremans R, Boeckx B, Hermans F, Arijs I, Cox B, Van Nieuwenhuysen E et al: Developing Organoids from Ovarian Cancer as Experimental and Preclinical Models. Stem Cell Reports. 2020, 14(4):717\u2013729 %U https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213671120300941.","DOI":"10.1016\/j.stemcr.2020.03.004"},{"key":"2665_CR22","doi-asserted-by":"crossref","unstructured":"Maenhoudt N, Vankelecom H: Protocol for establishing organoids from human ovarian cancer biopsies. STAR Protocols 2021, 2(2):100429 %U https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666166721001362.","DOI":"10.1016\/j.xpro.2021.100429"},{"key":"2665_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13122901","author":"J Bi","year":"2021","unstructured":"Bi J, Newtson AM, Zhang Y, Devor EJ, Samuelson MI, Thiel KW, et al. Successful patient-derived organoid culture of gynecologic cancers for disease modeling and drug sensitivity testing. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13122901.","journal-title":"Cancers (Basel)"},{"key":"2665_CR24","doi-asserted-by":"crossref","unstructured":"L\u00f5hmussaar K, Oka R, Espejo Valle-Inclan J, Smits MHH, Wardak H, Korving J, Begthel H, Proost N, Van De Ven M, Kranenburg OW et al: Patient-derived organoids model cervical tissue dynamics and viral oncogenesis in cervical cancer. Cell Stem Cell 2021, 28(8):1380\u20131396.e1386 %U https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1934590921001181.","DOI":"10.1016\/j.stem.2021.03.012"},{"key":"2665_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.108198","author":"H Huang","year":"2023","unstructured":"Huang H, Pan Y, Huang J, Zhang C, Liao Y, Du Q, et al. Patient-derived organoids as personalized avatars and a potential immunotherapy model in cervical cancer. iScience. 2023. https:\/\/doi.org\/10.1016\/j.isci.2023.108198.","journal-title":"iScience"},{"issue":"2","key":"2665_CR26","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","volume":"173","author":"F Sanchez-Vega","year":"2018","unstructured":"Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, et al. Oncogenic signaling pathways in The Cancer Genome Atlas. Cell. 2018;173(2):321-337.e310.","journal-title":"Cell"},{"key":"2665_CR27","doi-asserted-by":"publisher","unstructured":"Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, Rudolph JE, Yaeger R, Soumerai T, Nissan MH, et al. OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol. 2017(2017):10.1200\/PO.17.00011. https:\/\/doi.org\/10.1200\/PO.17.00011.","DOI":"10.1200\/PO.17.00011"},{"issue":"1","key":"2665_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-018-0531-8","volume":"10","author":"D Tamborero","year":"2018","unstructured":"Tamborero D, Rubio-Perez C, Deu-Pons J, Schroeder MP, Vivancos A, Rovira A, et al. Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations. Genome Med. 2018;10(1):25.","journal-title":"Genome Med"},{"issue":"2","key":"2665_CR29","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3109\/0284186X.2014.973613","volume":"54","author":"P Bager","year":"2015","unstructured":"Bager P, Wohlfahrt J, S\u00f8rensen E, Ullum H, H\u00f8gdall CK, Palle C, et al. Common filaggrin gene mutations and risk of cervical cancer. Acta Oncol. 2015;54(2):217\u201323.","journal-title":"Acta Oncol"},{"key":"2665_CR30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/978-3-030-70115-4_2","volume-title":"The role of glycosylation in health and disease","author":"I Bagdonaite","year":"2021","unstructured":"Bagdonaite I, Pallesen EM, Nielsen MI, Bennett EP, Wandall HH. Mucin-type O-GalNAc glycosylation in health and disease. In: The role of glycosylation in health and disease. 2021. p. 25\u201360."},{"issue":"1","key":"2665_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-022-01376-9","volume":"15","author":"J Liu","year":"2022","unstructured":"Liu J, Li Z, Lu T, Pan J, Li L, Song Y, et al. Genomic landscape, immune characteristics and prognostic mutation signature of cervical cancer in China. BMC Med Genomics. 2022;15(1):231.","journal-title":"BMC Med Genomics"},{"issue":"7","key":"2665_CR32","first-page":"1961","volume":"60","author":"CX Liu","year":"2000","unstructured":"Liu CX, Musco S, Lisitsina NM, Forgacs E, Minna JD, Lisitsyn NA. LRP-DIT, a putative endocytic receptor gene, is frequently inactivated in non-small cell lung cancer cell lines. Cancer Res. 2000;60(7):1961\u20137.","journal-title":"Cancer Res"},{"issue":"2","key":"2665_CR33","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/joim.12019","volume":"273","author":"L Claesson-Welsh","year":"2013","unstructured":"Claesson-Welsh L, Welsh M. VEGFA and tumour angiogenesis. J Intern Med. 2013;273(2):114\u201327.","journal-title":"J Intern Med"},{"issue":"11","key":"2665_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176181","volume":"12","author":"LA Albacker","year":"2017","unstructured":"Albacker LA, Wu J, Smith P, Warmuth M, Stephens PJ, Zhu P, et al. Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion. PLoS ONE. 2017;12(11):e0176181.","journal-title":"PLoS ONE"},{"issue":"3","key":"2665_CR35","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41416-021-01400-2","volume":"125","author":"E Schaafsma","year":"2021","unstructured":"Schaafsma E, Fugle CM, Wang X, Cheng C. Pan-cancer association of HLA gene expression with cancer prognosis and immunotherapy efficacy. Br J Cancer. 2021;125(3):422\u201332.","journal-title":"Br J Cancer"},{"issue":"1","key":"2665_CR36","doi-asserted-by":"publisher","first-page":"25468","DOI":"10.1038\/s41598-024-75888-y","volume":"14","author":"EA Farshadi","year":"2024","unstructured":"Farshadi EA, Wang W, Mohammad F, van der Oost E, Doukas M, van Eijck CH, et al. Tumor organoids improve mutation detection of pancreatic ductal adenocarcinoma. Sci Rep. 2024;14(1):25468.","journal-title":"Sci Rep"},{"issue":"1","key":"2665_CR37","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1038\/s41467-019-11867-6","volume":"10","author":"M Kim","year":"2019","unstructured":"Kim M, Mun H, Sung CO, Cho EJ, Jeon HJ, Chun SM, et al. Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. Nat Commun. 2019;10(1):3991.","journal-title":"Nat Commun"},{"issue":"1","key":"2665_CR38","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1038\/s41598-020-59656-2","volume":"10","author":"R Kurilov","year":"2020","unstructured":"Kurilov R, Haibe-Kains B, Brors B. Assessment of modelling strategies for drug response prediction in cell lines and xenografts. Sci Rep. 2020;10(1):2849.","journal-title":"Sci Rep"},{"key":"2665_CR39","doi-asserted-by":"publisher","DOI":"10.1093\/biomethods\/bpaf012","author":"Y Chen","year":"2025","unstructured":"Chen Y, Zhang J, Zhang B, Lee HK, Xie S, Shen W, et al. Optimizing drug sensitivity assays in patient-derived tumor organoids: a comparison of IC50 estimation methods and experimental parameters. Biol Methods Protoc. 2025. https:\/\/doi.org\/10.1093\/biomethods\/bpaf012.","journal-title":"Biol Methods Protoc"},{"key":"2665_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26082382","author":"S Mirzaei","year":"2021","unstructured":"Mirzaei S, Hushmandi K, Zabolian A, Saleki H, Torabi SMR, Ranjbar A, et al. Elucidating role of reactive oxygen species (ROS) in cisplatin chemotherapy: a focus on molecular pathways and possible therapeutic strategies. Molecules. 2021. https:\/\/doi.org\/10.3390\/molecules26082382.","journal-title":"Molecules"},{"issue":"4","key":"2665_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/or.2022.8293","volume":"47","author":"L Yang","year":"2022","unstructured":"Yang L, Xie H-J, Li Y-Y, Wang X, Liu X-X, Mai J. Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer. Oncol Rep. 2022;47(4):1\u201311.","journal-title":"Oncol Rep"},{"issue":"43","key":"2665_CR42","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"45","key":"2665_CR43","first-page":"145","volume":"9","author":"JD Amaral","year":"2010","unstructured":"Amaral JD, Xavier JM, Steer CJ, Rodrigues CM. The role of p53 in apoptosis. Discov Med. 2010;9(45):145\u201352.","journal-title":"Discov Med"},{"issue":"6","key":"2665_CR44","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41568-019-0143-7","volume":"19","author":"LN Kent","year":"2019","unstructured":"Kent LN, Leone G. The broken cycle: E2F dysfunction in cancer. Nat Rev Cancer. 2019;19(6):326\u201338.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2665_CR45","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.bbagrm.2014.03.013","volume":"1849","author":"G Bretones","year":"2015","unstructured":"Bretones G, Delgado MD, Le\u00f3n J. Myc and cell cycle control. Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms. 2015;1849(5):506\u201316.","journal-title":"Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms"},{"issue":"2","key":"2665_CR46","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1101\/gad.949802","volume":"16","author":"B Ren","year":"2002","unstructured":"Ren B, Cam H, Takahashi Y, Volkert T, Terragni J, Young RA, et al. E2F integrates cell cycle progression with DNA repair, replication, and G2\/M checkpoints. Genes Dev. 2002;16(2):245\u201356.","journal-title":"Genes Dev"},{"issue":"12","key":"2665_CR47","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.bbamcr.2006.09.006","volume":"1763","author":"M Schrader","year":"2006","unstructured":"Schrader M, Fahimi HD. Peroxisomes and oxidative stress. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2006;1763(12):1755\u201366.","journal-title":"Biochimica et Biophysica Acta (BBA)-Molecular Cell Research"},{"issue":"16","key":"2665_CR48","doi-asserted-by":"publisher","first-page":"R622","DOI":"10.1016\/j.cub.2012.07.004","volume":"22","author":"SS Cao","year":"2012","unstructured":"Cao SS, Kaufman RJ. Unfolded protein response. Curr Biol. 2012;22(16):R622\u20136.","journal-title":"Curr Biol"},{"issue":"8","key":"2665_CR49","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.cellsig.2016.05.007","volume":"28","author":"J Wang","year":"2016","unstructured":"Wang J, Yang X, Zhang J. Bridges between mitochondrial oxidative stress, ER stress and mTOR signaling in pancreatic \u03b2 cells. Cell Signal. 2016;28(8):1099\u2013104.","journal-title":"Cell Signal"},{"issue":"3","key":"2665_CR50","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1158\/1078-0432.CCR-14-3081","volume":"22","author":"O Arqu\u00e9s","year":"2016","unstructured":"Arqu\u00e9s O, Chicote I, Puig I, Tenbaum SP, Argil\u00e9s G, Dienstmann R, et al. Tankyrase inhibition blocks Wnt\/\u03b2-catenin pathway and reverts resistance to PI3K and AKT inhibitors in the treatment of colorectal cancer. Clin Cancer Res. 2016;22(3):644\u201356.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2665_CR51","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1124\/mol.119.117978","volume":"97","author":"Z Zhong","year":"2020","unstructured":"Zhong Z, Virshup DM. Wnt signaling and drug resistance in cancer. Mol Pharmacol. 2020;97(2):72\u201389.","journal-title":"Mol Pharmacol"},{"issue":"5","key":"2665_CR52","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1158\/1078-0432.CCR-07-2238","volume":"14","author":"LP Martin","year":"2008","unstructured":"Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res. 2008;14(5):1291\u20135.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2665_CR53","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/cancers11010119","volume":"11","author":"G Damia","year":"2019","unstructured":"Damia G, Broggini M. Platinum resistance in ovarian cancer: role of DNA repair. Cancers. 2019;11(1):119.","journal-title":"Cancers"},{"issue":"1","key":"2665_CR54","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1038\/s41467-022-28569-1","volume":"13","author":"S Koster","year":"2022","unstructured":"Koster S, Gurumurthy RK, Kumar N, Prakash PG, Dhanraj J, Bayer S, et al. Modelling chlamydia and HPV co-infection in patient-derived ectocervix organoids reveals distinct cellular reprogramming. Nat Commun. 2022;13(1):1030.","journal-title":"Nat Commun"},{"key":"2665_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2023.154653","volume":"248","author":"ZMS Haghighi","year":"2023","unstructured":"Haghighi ZMS, Tabatabaei T, Rafigh M, Karampour R, Babaei F, Amjad ZS, et al. Human papillomavirus maybe is a critical player in the regulation of chemoresistance related factors (P53, Rb, TWIST, Bcl-2, Bcl-XL, c-IAP2, cytochrome C, and caspase 3) in breast cancer. Pathol Res Pract. 2023;248:154653.","journal-title":"Pathol Res Pract"},{"key":"2665_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvr.2025.200323","volume":"20","author":"MA Strikwerda","year":"2025","unstructured":"Strikwerda MA, Weerstand SA, Burchell GL, Tromp JM, Mom CH, de Gruijl TD. The immunological heterogeneity of squamous cell carcinoma and adenocarcinoma of the uterine cervix: a systematic review. Tumour Virus Res. 2025;20:200323.","journal-title":"Tumour Virus Res"},{"issue":"5","key":"2665_CR57","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.4049\/jimmunol.178.5.3186","volume":"178","author":"UA Hasan","year":"2007","unstructured":"Hasan UA, Bates E, Takeshita F, Biliato A, Accardi R, Bouvard V, et al. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol. 2007;178(5):3186\u201397.","journal-title":"J Immunol"},{"key":"2665_CR58","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"740","author":"S Dasari","year":"2014","unstructured":"Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364\u201378.","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"2665_CR59","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1038\/s41401-021-00616-5","volume":"42","author":"M Ghanaat","year":"2021","unstructured":"Ghanaat M, Goradel NH, Arashkia A, Ebrahimi N, Ghorghanlu S, Malekshahi ZV, et al. Virus against virus: strategies for using adenovirus vectors in the treatment of HPV-induced cervical cancer. Acta Pharmacol Sin. 2021;42(12):1981\u201390.","journal-title":"Acta Pharmacol Sin"},{"key":"2665_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107669","author":"MD Nyquist","year":"2020","unstructured":"Nyquist MD, Corella A, Coleman I, De Sarkar N, Kaipainen A, Ha G, et al. Combined TP53 and RB1 loss promotes prostate cancer resistance to a spectrum of therapeutics and confers vulnerability to replication stress. Cell Rep. 2020. https:\/\/doi.org\/10.1016\/j.celrep.2020.107669.","journal-title":"Cell Rep"},{"key":"2665_CR61","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/rmv.1823","volume":"25","author":"J Chen","year":"2015","unstructured":"Chen J. Signaling pathways in HPV\u2010associated cancers and therapeutic implications. Rev Med Virol. 2015;25:24\u201353.","journal-title":"Rev Med Virol"},{"key":"2665_CR62","doi-asserted-by":"crossref","unstructured":"Valdivia A, Cowan M, Cardenas H, Isac AM, Zhao G, Huang H, Matei D. E2F1 mediates competition, proliferation and response to cisplatin in cohabitating resistant and sensitive ovarian cancer cells. Front Oncol. 2024, 14: 2024.","DOI":"10.3389\/fonc.2024.1304691"},{"issue":"1","key":"2665_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09528-x","volume":"22","author":"Y He","year":"2022","unstructured":"He Y, Han S-B, Liu Y, Zhang J-J, Wu Y-M. Role of APOA1 in the resistance to platinum-based chemotherapy in squamous cervical cancer. BMC Cancer. 2022;22(1):411.","journal-title":"BMC Cancer"},{"issue":"1","key":"2665_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-90714-9","volume":"15","author":"B Thibault","year":"2025","unstructured":"Thibault B, Thole A, D\u2019Angelo R, Basset C, Guillermet-Guibert J. PI3K\u03b1-specific inhibitor BYL-719 synergizes with cisplatin in vitro in PIK3CA-mutated ovarian cancer cells. Sci Rep. 2025;15(1):6265.","journal-title":"Sci Rep"},{"issue":"4","key":"2665_CR65","first-page":"1496","volume":"5","author":"CH Wong","year":"2015","unstructured":"Wong CH, Ma BB, Cheong HT, Hui CW, Hui EP, Chan AT. Preclinical evaluation of PI3K inhibitor BYL719 as a single agent and its synergism in combination with cisplatin or MEK inhibitor in nasopharyngeal carcinoma (NPC). Am J Cancer Res. 2015;5(4):1496\u2013506.","journal-title":"Am J Cancer Res"},{"issue":"2","key":"2665_CR66","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1177\/03008916211073621","volume":"109","author":"G Bogani","year":"2023","unstructured":"Bogani G, Chiappa V, Bini M, Ronzulli D, Indini A, Conca E, et al. BYL719 (alpelisib) for the treatment of PIK3CA-mutated, recurrent\/advanced cervical cancer. Tumori. 2023;109(2):244\u20138.","journal-title":"Tumori"},{"issue":"14","key":"2665_CR67","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20143383","volume":"20","author":"JJ Liu","year":"2019","unstructured":"Liu JJ, Ho JY, Lee HW, Baik MW, Kim O, Choi YJ, et al. Inhibition of phosphatidylinositol 3-kinase (PI3K) signaling synergistically potentiates antitumor efficacy of paclitaxel and overcomes paclitaxel-mediated resistance in cervical cancer. Int J Mol Sci. 2019;20(14):3383.","journal-title":"Int J Mol Sci"},{"key":"2665_CR68","doi-asserted-by":"crossref","unstructured":"Gurumurthy RK, Koster S, Kumar N, Meyer TF, Chumduri C. Patient-derived and mouse endo-ectocervical organoid generation, genetic manipulation and applications to model infection. Nat Protoc. 2022, 17(7):1658\u20131690 %U https:\/\/www.nature.com\/articles\/s41596-41022-00695-41596.","DOI":"10.1038\/s41596-022-00695-6"},{"issue":"5","key":"2665_CR69","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/bioinformatics\/btp698","volume":"26","author":"H Li","year":"2010","unstructured":"Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics. 2010;26(5):589\u201395.","journal-title":"Bioinformatics"},{"key":"2665_CR70","volume-title":"Genomics in the cloud","author":"G van der Auwera","year":"2020","unstructured":"van der Auwera G, O\u2019Connor BD. Genomics in the cloud. Sebastopol, CA: O\u2019Reilly Media; 2020."},{"issue":"16","key":"2665_CR71","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38(16):e164.","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"2665_CR72","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda A, Lin D-C, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747\u201356.","journal-title":"Genome Res"},{"issue":"1","key":"2665_CR73","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-022-08357-3","volume":"23","author":"F Manders","year":"2022","unstructured":"Manders F, Brandsma AM, de Kanter J, Verheul M, Oka R, van Roosmalen MJ, et al. MutationalPatterns: the one stop shop for the analysis of mutational processes. BMC Genomics. 2022;23(1):134.","journal-title":"BMC Genomics"},{"key":"2665_CR74","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-1-0716-2756-3_2","volume":"2584","author":"J Ulbrich","year":"2023","unstructured":"Ulbrich J, Lopez-Salmeron V, Gerrard I. BD Rhapsody\u2122 Single-Cell Analysis System workflow: From sample to multimodal single-cell sequencing data. Methods Mol Biol. 2023;2584:29\u201356.","journal-title":"Methods Mol Biol"},{"issue":"1","key":"2665_CR75","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13059-017-1382-0","volume":"19","author":"FA Wolf","year":"2018","unstructured":"Wolf FA, Angerer P, Theis FJ. SCANPY: large-scale single-cell gene expression data analysis. Genome Biol. 2018;19(1):15.","journal-title":"Genome Biol"},{"issue":"1","key":"2665_CR76","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btac757","volume":"39","author":"Z Fang","year":"2023","unstructured":"Fang Z, Liu X, Peltz G. GSEApy: a comprehensive package for performing gene set enrichment analysis in Python. Bioinformatics. 2023;39(1):btac757.","journal-title":"Bioinformatics"}],"container-title":["BMC Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12915-026-02665-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12915-026-02665-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12915-026-02665-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:02:27Z","timestamp":1789956147000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12915-026-02665-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2665"],"URL":"https:\/\/doi.org\/10.1186\/s12915-026-02665-w","relation":{},"ISSN":["1741-7007"],"issn-type":[{"value":"1741-7007","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"31 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the by the Ethics Committee of the First Affiliated Hospital of Fujian Medical University (MRCTA, ECFAH of FMU [2021]435).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"197"}}